TP53 and cervical carcinoma: Given this, we determined that the XRCC1 rs25487 heterozygote genotype combined with the TP53 rs1042522 heterozygote genotype was associated with an almost 4-fold (cases vs. negative controls) or 17-fold (cases vs. elderly group) increase in cervical cancer risk (cases vs. negative controls: OR = 4.63, 95% CI = 1.83–11.75, p = 0.00; cases vs. elderly group: OR = 17.61, 95% CI = 4.34–71.50, p = 0.00).